Clinical trials: Diabetes Mellitus II
Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus
Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus
Prospective, single center, double-blind, randomized pharmacodynamic experimental study. The study will enroll 150 subjects with ASCVD on optimal statin therapy as per physician and Diabetes Mellitus (DM) undergoing elective…
- Conditions
- Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus, Percutaneous Coronary Intervention
- Trial name
- ISS-DMII (NCT03258281)
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Inova Health Care Services
Diabetes Mellitus
A Pivotal Study to Evaluate Enlite™ Sensor Performance With iPro™2 in China
The purpose of this study is to demonstrate the performance and safety of the Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
- Trial name
- NCT03417466
- Testing
- Enlite 1 connected to iPro2 recorder
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes
Evaluating an Analogy-Based Consultation Approach for Insulin-Treated Type 2 Diabetes Patients
The goal of this retrospective interventional study is to learn whether a new consultation approach called M2-PRIME can help improve blood sugar control in people with type 2 diabetes who use insulin and have high blood sugar…
- Trial name
- ANALOGIES01 (NCT07265245)
- Testing
- M2-PRIME
- Where
- Malaysia
- Volunteers
- 106 people
- Sponsor
- Ministry of Health, Malaysia
Type 1 Diabetes Mellitus
Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes
This is a randomized placebo controlled study to test whether a single 14 course of treatment with the anti-CD3 monoclonal antibody, hOKT3gamma1(Ala-Ala),Teplizumab will prevent the loss of insulin secretory capacity in…
- Trial name
- NCT00378508
- Testing
- mAb hOKT3gamma1(Ala-Ala), Teplizumab
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Yale University
Type II Diabetes Mellitus, Dyslipidemia
Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
This is a sixteen-week double-blind active-controlled follow-on and 28-week single-blind extension study for patients who participated in study NK-104-305.
- Trial name
- NCT00344370
- Testing
- Pitavastatin, Atorvastatin
- Where
- 35 sites in Denmark, Germany and 4 more
- Volunteers
- 214 people
- Sponsor
- Kowa Research Europe
Diabetes Mellitus, Type 1
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
Anti-CD3 monoclonal antibody (a.k.a. hOKT3gamma1 [Ala-Ala],teplizumab, MGA031) is a humanized antibody that is commonly used to prevent organ rejection.
- Trial name
- AbATE (NCT00129259)
- Testing
- Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
The goal of this application is to evaluate the safety and efficacy of atorvastatin as a potential treatment to preserve beta cell function in children and young adults with newly diagnosed type 1 diabetes (T1DM).
- Trial name
- TIDM (NCT00529191)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Philadelphia
HTLV-I Infection, T Cell Leukemia
Anti-Tac for Treatment of Leukemia
The purpose of the study was to determine: (1) the toxicity and maximum tolerated dose (MTD) of humanized anti-Tac (daclizumab), (Zenapax(Registered Trademark)) in patients with adult T-cell leukemia/lymphoma (ATL); (2) to define…
- Trial name
- NCT00001941
- Testing
- daclizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Bone Metabolism
Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.
The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.
- Trial name
- NCT00708175
- Testing
- Pioglitazone
- Where
- 34 sites in United States
- Volunteers
- 156 people
- Sponsor
- Takeda
Severe Insulin Resistance
Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance
Study Description: Patients with mutations of the insulin receptor have diabetes that is challenging to control with conventional therapies, leading to early morbidity and mortality.
- Trial name
- NCT00085982
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus
A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China
The purpose of this study is to demonstrate the performance and safety of the Guardian™ Sensor (3) over 170 hours (7 days) when inserted in the abdomen used in subjects age 14 - 75 years with the Guardian™ Connect System.
- Trial name
- NCT03710083
- Testing
- Guardian™ Sensor (3)
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type II
Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has sponsored a consortium of investigators to conduct a clinical treatment trial, Treatment Options for type…
- Trial name
- TODAY (NCT00081328)
- Testing
- Metformin, Rosiglitazone, Lifestyle Program
- Where
- 16 sites in United States
- Volunteers
- 699 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)